Delisting riskPopularity #3,598
TNYA · NASDAQ · Biotechnology

Tenaya Therapeutics (TNYA)

Develops gene therapies and small molecules for genetically defined heart diseases.

$0.6811
After-hours close−0.01 (−1.28%)
At close$0.6899(+2.39%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000001
Cost of revenue332200020−420
Gross profit−3−3−2−2000−204−21
282832292725282221251945
Research & development232325232019211715151517
567666676655
General & administrative000066676655
Other expenses0000000−204−223
Operating income−31−31−34−31−27−25−28−24−21−21−20−44
222111111111
Interest income211111111111
Other non-operating income−2−2−2−1−1−1−1−1−1−1−1−1
Income before tax−29−30−32−29−26−24−27−23−20−20−19−43
Net income from continuing operations−29−30−32−29−26−24−27−23−20−20−19−43
Net income−29−30−32−29−26−24−27−23−20−20−19−43
EPS, basic−$0.39−$0.44−$0.40−$0.34−$0.30−$0.28−$0.24−$0.14−$0.12−$0.12−$0.09−$0.20
EPS, diluted−$0.39−$0.44−$0.40−$0.34−$0.30−$0.28−$0.24−$0.14−$0.12−$0.12−$0.09−$0.20
Weighted average shares, basic746881868686110163163153217218
Weighted average shares, diluted746881868686110163163153217218
EBITDA−26−27−30−27−24−22−24−21−18−18−18−42
Depreciation & amortization332222322222
EBIT−29−30−32−29−26−24−27−23−20−20−19−43